CSIMarket
 


Casi Pharmaceuticals inc   (CASI)
Other Ticker:  
 
 

CASI's Revenue Growth by Quarter and Year

Casi Pharmaceuticals Inc 's Revenue results by quarter and year




CASI Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 9.16 4.82 1.46
III Quarter September 10.21 8.11 4.24 2.79
II Quarter June 8.57 7.16 2.67 -0.80
I Quarter March 9.06 5.74 3.41 -0.12
FY   27.84 30.17 15.14 3.33



CASI Revenue third quarter 2022 Y/Y Growth Comment
Casi Pharmaceuticals inc reported Revenue improvement of 25.93% year on year in the third quarter 2022, to $ 10.21 millions, this is lower than Casi Pharmaceuticals Inc 's recent average Revenue improvement of 29.31%.

Looking into third quarter 2022 results within Biotechnology & Pharmaceuticals industry 40 other companies have achieved higher Revenue growth. While Casi Pharmaceuticals Inc ' s Revenue rise of 25.93% ranks overall at the positon no. 933 in the third quarter 2022.




CASI Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - 90.04 % 230.14 % -
III Quarter September 25.93 % 91.27 % 51.97 % -
II Quarter June 19.69 % 168.16 % - -
I Quarter March 57.84 % 68.33 % - -
FY   - 99.27 % 354.65 % -

Financial Statements
Casi Pharmaceuticals Inc 's third quarter 2022 Revenue $ 10.21 millions CASI's Income Statement
Casi Pharmaceuticals Inc 's third quarter 2021 Revenue $ 8.11 millions Quarterly CASI's Income Statement
New: More CASI's historic Revenue Growth >>


CASI Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - 12.95 % 13.68 % -47.67 %
III Quarter September 19.17 % 13.27 % 58.8 % -
II Quarter June -5.41 % 24.74 % -21.7 % -
I Quarter March -1.09 % 19.09 % 133.56 % -
FY (Year on Year)   - 99.27 % 354.65 % -




Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #41
Healthcare Sector #173
Overall #933

Revenue Y/Y Growth Statistics
High Average Low
105.85 % 29.31 % 4.21 %
(Mar 31 2020)   (Jun 30 2022)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #41
Healthcare Sector #173
Overall #933
Revenue Y/Y Growth Statistics
High Average Low
105.85 % 29.31 % 4.21 %
(Mar 31 2020)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Casi Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
132.73 % 16.92 % -47.49 %
(Mar 31 2020)  


CASI's III. Quarter Q/Q Revenue Comment
Casi Pharmaceuticals inc achieved in the III. Quarter 2022 above company average sequential Revenue jump of 19.17%, to $ 10.21 millions, from $8.57 millions in the second quarter.
Biotechnology & Pharmaceuticals company is impressively improving, not just reporting above average increase, and also improving rate, Grace Anderson, Biotechnology & Pharmaceuticals industry veteran situated in Philadelphia said.

Within Biotechnology & Pharmaceuticals industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Casi Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 507.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #37
Healthcare Sector #128
Overall #507
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #37
Healthcare Sector #128
Overall #507
Revenue Q/Q Growth Statistics
High Average Low
132.73 % 16.92 % -47.49 %
(Mar 31 2020)  


CASI's III. Quarter Q/Q Revenue Comment
Casi Pharmaceuticals inc achieved in the III. Quarter 2022 above company average sequential Revenue jump of 19.17%, to $ 10.21 millions, from $8.57 millions in the second quarter.
Casi Pharmaceuticals Inc is impressively improving, not only claiming better then regular growth, but also accelerating speed, Grace Anderson, Biotechnology & Pharmaceuticals industry veteran situated in Philadelphia said.

Within Biotechnology & Pharmaceuticals industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Casi Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 507.


Casi Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 37.01 $ 34.91 $ 33.49 $ 30.17 $ 25.83
Y / Y Revenue Growth (TTM) 43.26 % 58.93 % 91.71 % 99.25 % 119.24 %
Year on Year Revenue Growth Overall Ranking # 606 # 539 # 403 # 229 # 271
Seqeuential Revenue Change (TTM) 6.02 % 4.21 % 11.02 % 16.79 % 17.62 %
Seq. Revenue Growth (TTM) Overall Ranking # 933 # 1395 # 662 # 502 # 497




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2022 period, Casi Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 37 millions, company would post below average annual Revenue growth of 17.62% year on year, if the fiscal year would end at Sep 30 2022.
A slow-down in the Casi Pharmaceuticals Inc 's Revenue growth from the 8.57% growth in Jun 30 2022.

In the Healthcare sector 121 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 539 to 606.

Revenue TTM Q/Q Growth Statistics
High Average Low
105.85 %
29.31 %
4.21 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 41
Healthcare Sector # 122
Overall # 606

Revenue TTM Y/Y Growth Statistics
High Average Low
547.46 %
175.77 %
43.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 173
S&P 500 # 933
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2022 period, Casi Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 37 millions, company would post below average annual Revenue growth of 43.26% year on year, if the fiscal year would end at Sep 30 2022.
A slow-down in the Casi Pharmaceuticals Inc 's Revenue growth from the 8.57% growth in Jun 30 2022.

In the Healthcare sector 121 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 539 to 606.

Revenue TTM Q/Q Growth Statistics
High Average Low
105.85 %
29.31 %
4.21 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 41
Healthcare Sector # 122
Overall # 606

Revenue TTM Y/Y Growth Statistics
High Average Low
547.46 %
175.77 %
43.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 173
S&P 500 # 933




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CASI's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for CASI's Competitors
Revenue Growth for Casi Pharmaceuticals Inc 's Suppliers
Revenue Growth for CASI's Customers

You may also want to know
CASI's Annual Growth Rates CASI's Profitability Ratios CASI's Asset Turnover Ratio CASI's Dividend Growth
CASI's Roe CASI's Valuation Ratios CASI's Financial Strength Ratios CASI's Dividend Payout Ratio
CASI's Roa CASI's Inventory Turnover Ratio CASI's Growth Rates CASI's Dividend Comparisons



Companies with similar Revenue jump for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Predictive Oncology Inc 45.32%$ 45.324 millions
Harmony Biosciences Holdings inc 45.18%$ 45.179 millions
Insmed Inc44.86%$ 44.855 millions
Seaspine Holdings Corporation44.57%$ 44.573 millions
Tela Bio Inc 44.55%$ 44.552 millions
Sorrento Therapeutics Inc 44.25%$ 44.255 millions
Luna Innovations Inc43.41%$ 43.406 millions
Alphatec Holdings Inc 42.87%$ 42.874 millions
Sight Sciences Inc 42.56%$ 42.562 millions
Urogen Pharma Ltd 41.81%$ 41.811 millions
Cumberland Pharmaceuticals Inc 41.38%$ 41.381 millions
Alnylam Pharmaceuticals Inc 40.86%$ 40.863 millions
Endonovo Therapeutics Inc 40.69%$ 40.693 millions
Oak Street Health Inc 40.39%$ 40.391 millions
Akoya Biosciences Inc 39.89%$ 39.893 millions
Y mabs Therapeutics inc 39.84%$ 39.844 millions
Tscan Therapeutics Inc 39.43%$ 39.428 millions
Orthopediatrics Corp39.36%$ 39.360 millions
Xencor Inc38.69%$ 38.693 millions
23andme Holding Co 37.05%$ 37.053 millions
Carlisle Companies Incorporated36.37%$ 36.371 millions
Privia Health Group Inc 36.33%$ 36.329 millions
Myovant Sciences Ltd 34.56%$ 34.559 millions
Assertio Holdings inc 34.31%$ 34.312 millions
Butterfly Network Inc 34.18%$ 34.177 millions
Inspiremd Inc 33.61%$ 33.613 millions
Zai Lab Limited33.49%$ 33.494 millions
Natera Inc 33.22%$ 33.217 millions
Electrocore Inc 32.88%$ 32.877 millions
Eiger Biopharmaceuticals Inc 32.41%$ 32.412 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

PNRG's Profile

Stock Price

PNRG's Financials

Business Description

Fundamentals

Charts & Quotes

PNRG's News

Suppliers

PNRG's Competitors

Customers & Markets

Economic Indicators

PNRG's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071